quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·144d
PRRelease
LENZ Therapeutics Inc. logo

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

LENZ· LENZ Therapeutics Inc.
Health Care
Original source

Companies

  • LENZ
    LENZ Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 14UpdatePiper Sandler$51.00
  • Mar 18UpdateTD Cowen$60.00
  • Sep 27UpdateRaymond James$37.00
  • Aug 12UpdateH.C. Wainwright$38.00
  • Apr 15UpdateWilliam Blair-
  • Apr 15UpdateLeerink Partners$32.00

Related

  • PR4d
    LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
  • SEC15d
    SEC Form SCHEDULE 13G filed by LENZ Therapeutics Inc.
  • INSIDER25d
    SEC Form 4 filed by George Jeffrey P.
  • INSIDER25d
    SEC Form 4 filed by Schimmelpennink Evert B.
  • INSIDER25d
    SEC Form 4 filed by Chevallard Daniel R.
  • SEC30d
    SEC Form S-8 filed by LENZ Therapeutics Inc.
  • SEC30d
    SEC Form 10-K filed by LENZ Therapeutics Inc.
  • SEC31d
    LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022